disease generalized arterial calcification of infants (GACI), closed a $49 million Series A round from investors including Sanofi (NYSE: [[ticker:SNY]]) and Novo Nordisk (NYSE: [[ticker:NVO]]).
—Cambridge-based X4 Pharmaceuticals raised $19 million in a Series B round that will support clinical studies of its immunotherapy in cancer and the rare WHIM syndrome.
—MIT spinout Torque Therapeutics of Cambridge announced $25 million in funding and a plan to attach an extra drug payload to cell therapies for better cancer treatment.
—Syapse of San Francisco raised $30 million to expand operations and bring its precision oncology software to more physicians and cancer patients.
—Locus Biosciences of Research Triangle Park, NC, announced a $19 million Series A round that will finance clinical tests of a “smart bomb” antimicrobial developed using CRISPR-Cas3.
—Arvinas expanded its 2015 alliance with Genentech, which grants an ongoing license to the New Haven, CT, biotech’s drug technology. The revised pact adds new disease targets, making Arvinas eligible for potential payments topping $650 million.
Ben Fidler and Frank Vinlaun contributed to this report.
